SG11202003390UA - Therapeutic agents for neurodegenerative diseases - Google Patents
Therapeutic agents for neurodegenerative diseasesInfo
- Publication number
- SG11202003390UA SG11202003390UA SG11202003390UA SG11202003390UA SG11202003390UA SG 11202003390U A SG11202003390U A SG 11202003390UA SG 11202003390U A SG11202003390U A SG 11202003390UA SG 11202003390U A SG11202003390U A SG 11202003390UA SG 11202003390U A SG11202003390U A SG 11202003390UA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic agents
- neurodegenerative diseases
- neurodegenerative
- diseases
- therapeutic
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762574137P | 2017-10-18 | 2017-10-18 | |
PCT/US2018/018420 WO2019078915A1 (en) | 2017-10-18 | 2018-02-15 | Therapeutic agents for neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003390UA true SG11202003390UA (en) | 2020-05-28 |
Family
ID=66174216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003390UA SG11202003390UA (en) | 2017-10-18 | 2018-02-15 | Therapeutic agents for neurodegenerative diseases |
Country Status (14)
Country | Link |
---|---|
US (1) | US11793782B2 (en) |
EP (1) | EP3697399A1 (en) |
JP (1) | JP2021500342A (en) |
KR (1) | KR102549684B1 (en) |
CN (1) | CN111542314B (en) |
AU (1) | AU2018351709B2 (en) |
BR (1) | BR112020007657A2 (en) |
CA (1) | CA3079194A1 (en) |
IL (1) | IL273929A (en) |
MA (1) | MA50383A (en) |
MX (1) | MX2020003427A (en) |
RU (1) | RU2763425C2 (en) |
SG (1) | SG11202003390UA (en) |
WO (1) | WO2019078915A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
JP7337081B2 (en) * | 2018-02-15 | 2023-09-01 | イントラバイオ リミティド | Therapeutic agents for treating restless legs syndrome |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2517845A1 (en) * | 2003-03-06 | 2004-09-23 | Celgene Corporation | Selective cytokine inhibitory drugs for treating disorders of the central nervous system |
RU2458049C2 (en) * | 2003-09-17 | 2012-08-10 | Ксенопорт, Инк. | Treatment and prevention of restless leg syndrome with using gaba analogue prodrugs |
MX2009012188A (en) * | 2007-05-11 | 2010-02-24 | Univ Jefferson | Methods of treatment and prevention of neurodegenerative diseases and disorders. |
EP2289886A1 (en) * | 2009-08-31 | 2011-03-02 | Institut d'Investigacions Biomédiques August PI I Sunyer | Peptoid agonists of nerve growth factor and their use as medicaments |
CA2785056A1 (en) * | 2009-12-22 | 2011-07-21 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
TN2010000251A1 (en) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-ACETYL-DL-LEUCINE MEDICINAL NEURO AND RETINO PROTECTOR |
PL3103469T3 (en) | 2010-06-25 | 2021-09-06 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
EP3111935A4 (en) * | 2014-02-27 | 2017-03-15 | Medrx Co., Ltd. | Pramipexole-containing transdermal patch for treatment of neurodegenerative disease |
ME03454B (en) * | 2016-08-11 | 2020-01-20 | Intrabio Ltd | Therapeutic agents for neurodegenerative diseases |
-
2018
- 2018-02-15 MX MX2020003427A patent/MX2020003427A/en unknown
- 2018-02-15 RU RU2020115710A patent/RU2763425C2/en active
- 2018-02-15 US US16/756,948 patent/US11793782B2/en active Active
- 2018-02-15 WO PCT/US2018/018420 patent/WO2019078915A1/en unknown
- 2018-02-15 MA MA050383A patent/MA50383A/en unknown
- 2018-02-15 KR KR1020207014143A patent/KR102549684B1/en active IP Right Grant
- 2018-02-15 JP JP2020521938A patent/JP2021500342A/en active Pending
- 2018-02-15 CN CN201880081672.6A patent/CN111542314B/en active Active
- 2018-02-15 EP EP18708286.2A patent/EP3697399A1/en active Pending
- 2018-02-15 CA CA3079194A patent/CA3079194A1/en active Pending
- 2018-02-15 BR BR112020007657-0A patent/BR112020007657A2/en unknown
- 2018-02-15 SG SG11202003390UA patent/SG11202003390UA/en unknown
- 2018-02-15 AU AU2018351709A patent/AU2018351709B2/en active Active
-
2020
- 2020-04-12 IL IL273929A patent/IL273929A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA50383A (en) | 2020-08-26 |
MX2020003427A (en) | 2020-09-14 |
EP3697399A1 (en) | 2020-08-26 |
BR112020007657A2 (en) | 2020-09-29 |
JP2021500342A (en) | 2021-01-07 |
KR20200074170A (en) | 2020-06-24 |
RU2020115710A3 (en) | 2021-11-18 |
RU2763425C2 (en) | 2021-12-29 |
AU2018351709B2 (en) | 2024-01-04 |
RU2020115710A (en) | 2021-11-18 |
AU2018351709A1 (en) | 2020-05-07 |
CN111542314B (en) | 2023-11-24 |
US20210196659A1 (en) | 2021-07-01 |
IL273929A (en) | 2020-05-31 |
CA3079194A1 (en) | 2019-04-25 |
US11793782B2 (en) | 2023-10-24 |
CN111542314A (en) | 2020-08-14 |
WO2019078915A1 (en) | 2019-04-25 |
KR102549684B1 (en) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201820166D0 (en) | Therapeutic agents | |
GB201709456D0 (en) | Therapeutic agents | |
GB201820165D0 (en) | Therapeutic agents | |
PL3600309T3 (en) | Therapeutic combinations for treating liver diseases | |
IL265902A (en) | Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases | |
SI3416631T1 (en) | Therapeutic agents for neurodegenerative diseases | |
GB201603104D0 (en) | Therapeutic agents | |
GB201805816D0 (en) | Therapeutic agents | |
IL281869A (en) | Therapeutic agent for neurodegenerative disease | |
IL273929A (en) | Therapeutic agents for neurodegenerative diseases | |
GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
GB201700553D0 (en) | Therapeutic agents | |
GB201600376D0 (en) | Novel therapeutic agents | |
SG11201705915VA (en) | Therapeutic agent for ischemic diseases | |
EP3560505A4 (en) | Novel therapeutic agent for prionoid diseases | |
GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
GB201820170D0 (en) | Therapeutic agents | |
GB201820160D0 (en) | Therapeutic agents | |
GB201820168D0 (en) | Therapeutic agents | |
GB201820164D0 (en) | Therapeutic agents | |
GB201820172D0 (en) | Therapeutic agents | |
GB201820162D0 (en) | Therapeutic agents | |
GB201811753D0 (en) | Therapeutic agents | |
GB201811467D0 (en) | Therapeutic agents |